



Your Preclinical Development Partner

Drug, Device, & Vaccine Development Services ♦ GLP & non-GLP ♦ Vivarium Services

Service Spotlight – GLP Toxicology Services



Toxicology studies are required to determine the adverse effects of drug candidates and the effect of dosage on toxicity. To assess toxicity, Noble offers a wide range of GLP and non-GLP toxicology services.

- Exploratory Toxicology
General Toxicology
Immunotoxicology and Immunogenicity
Development and Reproductive Toxicology
Toxicokinetics

With extensive experience in vaccine and drug development, Noble Life Sciences staff is dedicated to helping you complete your project in a timely and efficient manner. In addition to GLP toxicology services, Noble Life Sciences provides all aspects of the GLP process from design to regulatory support of your IND, IDE or PMA FDA submission. Learn More

Visit our booth (#1935) at the upcoming Society for Toxicology meeting March 12-15 in Baltimore, MD to learn more.

Service Options

- Dose range finding
Acute, subchronic, and chronic
Biodistribution
No Observable Effect Level (NOEL)/No Observable Adverse Effect Level (NOAEL)
Single and repeat dose
Local tolerance
Ocular and skin irritation evaluations
Median lethal dose (LD50)
Maximum tolerated dose (MTD)

Species Options

- Mouse
Guinea pig
Sheep
Mini pigs
Rat
Hamster
Goat
Ferret
Rabbit
Domestic swine

Routes of Administration

- Capsule
Intranasal
Dermal
Subcutaneous
Oral gavage
Intravenous
Intradermal
Continuous infusion
Dietary admixture

About Noble Life Sciences

Noble Life Sciences is a full-service preclinical contract research organization offering GLP and non-GLP services for the development of drugs, vaccines, and medical devices. From proof-of-concept studies to preclinical safety and efficacy studies, Noble Life Sciences has a wide range of services to meet your needs. For more information about Noble Life Sciences, visit www.noblelifesci.com

Preclinical Drug & Vaccine Development ♦ Medical Devices ♦ Vivarium Services ♦ GLP & non-GLP

March 2017 Newsletter